Daxor Corporation announces patient enrollment is complete and data analysis is underway in preparation for publication of the multi-center observational prospective study utilizing Daxor's BVA-100 (Blood Volume Analyzer, BVA) technology in hospitalized COVID-19 patients. NYU Langone Health, Wake Forest School of Medicine and OHSU have been enrolling subjects since the onset of the pandemic.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.65 USD | -2.92% | -0.92% | +0.52% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.52% | 46.38M | |
+3.82% | 12.52B | |
+5.50% | 8.84B | |
-3.25% | 5.39B | |
+5.57% | 5.16B | |
+2.65% | 5.11B | |
+14.54% | 4.51B | |
+16.44% | 4.44B | |
+1.53% | 4.01B | |
+1.56% | 3.75B |
- Stock Market
- Equities
- DXR Stock
- News Daxor Corporation
- Daxor Corporation Announces Patient Enrollment Completion and Updates Data Analysis